STOCK TITAN

Horizon Therapeutics Plc - HZNP STOCK NEWS

Welcome to our dedicated news page for Horizon Therapeutics Plc (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Therapeutics Plc's position in the market.

Rhea-AI Summary
Horizon Therapeutics announces date of Court Hearing for recommended cash offer by Pillartree Limited, a wholly owned subsidiary of Amgen Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
acquisition
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
acquisition
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
acquisition
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
acquisition
-
Rhea-AI Summary
Horizon Therapeutics ranks first in overall corporate reputation among rare disease patient groups worldwide, according to PatientView's survey. They also ranked first in 10 indicators including patient centricity and access to medicines. 91 rare disease patient advocacy groups were familiar with Horizon and 59 worked with the company. Horizon's global expansion and collaboration with patient advocacy groups contribute to their positive reputation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics announces second-quarter 2023 financial results with net sales of $945.0 million, representing 11% YoY growth excluding inflammation medicines. The company reports GAAP net income of $127.1 million and adjusted EBITDA of $320.4 million. TEPEZZA, KRYSTEXXA, and UPLIZNA contribute to strong sales growth. Cash position is $2.5 billion as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Rhea-AI Summary
HZNP: Horizon Therapeutics Announces 50 Awardees for 2023 #RAREis Global Advocate Grant, Awarding $5,000 to Rare Disease Patient Advocacy Organizations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
Horizon Therapeutics Plc

Nasdaq:HZNP

HZNP Rankings

HZNP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About HZNP

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.